Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vizoso, F.
Right arrow Articles by Méndez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vizoso, F.
Right arrow Articles by Méndez, J.
Related Collections
Right arrow Prognostic factors
Annals of Surgical Oncology 8:667-674 (2001)
© 2001 Society of Surgical Oncology

ORIGINAL ARTICLES

Lysozyme Expression by Breast Carcinomas, Correlation With Clinicopathologic Parameters, and Prognostic Significance

Francisco Vizoso, PhD, Elena Plaza, MD, Julio Vázquez, PhD, Carlos Serra, PhD, María L. Lamelas, PhD, Luis O. González, MD, Antonio M. Merino, PhD and Jaime Méndez, PhD

From the Servicios de Cirugía General (FV), Anestesia (EP), Ginecología (JV), and Anatomía Patológica (LOG) del Hospital de Jove de Gijón, Spain; Servicio de Cirugía General (CS) del Hospital Virgen de los Lirios de Alcoy, Alicante, Spain; Servicio de Anatomía Patológica (AMM) del Hospital de Cabueñes de Gijón, Spain; and Servicio de Cirugía General B (JM) del Hospital de Basurto, Bilbao, Spain.

Correspondence: Address correspondence and reprint requests to: Dr. Francisco Vizoso, Servicio de Cirugía General, Hospital de Jove, Avda. Eduardo Castro s/n, 33290 Gijón, Spain; Fax: 34-985-315710; E-mail: vazquezj{at}sego.es

Background: Here we evaluate the expression and prognostic value of lysozyme, a milk protein that is also synthesized by a significant percentage of breast carcinomas, in women with breast cancer.

Methods: Lysozyme expression was examined by immunohistochemical methods in a series of 177 breast cancer tissue sections. Staining was quantified by using the HSCORE system, which considers both the intensity and the percentage of cells staining at each intensity. The prognostic value of lysozyme was retrospectively evaluated by multivariate analysis that took into account conventional prognostic factors.

Results: A total of 126 of 177 carcinomas (69.4%) stained positive for this protein, but there were clear differences among them with regard to the intensity and percentage of stained cells. Lysozyme values were higher in well-differentiated and moderately differentiated tumors than in poorly differentiated tumors (P < .05). Similarly, lysozyme levels were higher in small and node-negative tumors than in large and node-positive tumors (P < .05). Moreover, results indicated that low lysozyme content predicted shorter relapse-free survival and overall survival (P < .005). Separate Cox multivariate analysis in subgroups of patients as defined by node status showed that lysozyme expression was an independent prognostic factor able to predict both relapse-free survival and overall survival in node-negative patients (P < .05).

Conclusions: Tumoral expression of lysozyme is associated with lesions of favorable evolution in breast cancer. This milk protein may be a new prognostic factor in patients with breast cancer.

Key Words: Lysozyme • Breast cancer • Prognosis • Prolactin receptors






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.